NULOJIX 250 mg powder for concentrate for solution for infusion

DRUG5 trials

Sponsors

Centre Hospitalier Universitaire De Nantes, Centre Hospitalier Universitaire De Nantes, Centre Hospitalier Universitaire Rouen, Centre Hospitalier Universitaire De Nantes, Medical University Of Vienna

Conditions

Early graft dysfunction after heart transplantKidney Transplant RecipientKidney transplantKidney transplantation

Phase 2

BELASBRIDGE : Belatacept as a replacement for CNIs 3 to 12 months post-transplantation in patients with early graft dysfunction

RecruitingCTIS2022-500299-71-00

Centre Hospitalier Universitaire De Nantes, Centre Hospitalier Universitaire De NantesKidney transplant

Start: 2024-05-03Target: 48Updated: 2024-02-29

Interest of belatacept as a non-nephrotoxic immunosuppressive treatment in cardiac transplant patients at risk of chronic renal failure.

Not yet recruitingCTIS2024-516541-40-00

Centre Hospitalier Universitaire De NantesEarly graft dysfunction after heart transplant

Target: 25Updated: 2026-01-07

SISTAR: Stratifying Immunosuppression to Allogenic Risk. A randomized, open label, assessor blinded, controlled, non-inferiority, safety study of half- vs standard dose immunosuppression in kidney transplant recipients with a well-matched donor.

Not yet recruitingCTIS2025-525091-29-00

Medical University Of ViennaKidney Transplant Recipient

Target: 120Updated: 2026-05-17

Phase 3

Screening for subclinical antibody mediated rejection and efficacy of belatacept in the context of de novo donor specific antibody after kidney transplantation / BEL-AMR

Not yet recruitingCTIS2024-516527-13-00

Centre Hospitalier Universitaire RouenKidney transplantation

Target: 290Updated: 2025-06-24

Phase 4

Comparison of the effects of Belatacept and Anticalcineurins on endothelial function in kidney transplant patients - BELAFENDO

RecruitingCTIS2024-515577-10-00

Centre Hospitalier Universitaire RouenKidney transplant

Start: 2025-07-24Target: 44Updated: 2026-01-26